Jubilant Biosys – Entering into the biologics
With the acquisition of an established European R&D site, Jubilant Biosys has expanded into the field of biologics, with a strong focus on monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and next-generation conjugate modalities. The addition of EU-based chemistry capabilities further enhances our ability to complement, support, and fast-track biologics programs. By combining the scientific expertise in biologics at our Saint-Julien site with Jubilant Biosys’s proven strengths in small molecules, we offer a unique and cost-effective hybrid delivery model for biopharma companies across Europe and the US.
The St Julien site is located in France, on the outskirts of Geneva, at the heart of the central European pharma & Biotech ecosystem
Saint-Julien-en-Genevois site: An experienced partner with capabilities in the identification and validation of preclinical candidates
Capabilities across ADC value chain
New Modalities: Feasibility at Saint-Julien Site
| Modality | Capability | Feasability |
| Antibody-Oligonucleotide Conjugate (AOC) | Yes | Accessible |
| Antibody-Peptide Conjugate (APC) | Yes | |
| Degrader-Antibody Conjugate (DAC) | Yes | |
| Antibody Fluorophore Conjugate | Yes | |
| Immune Stimulating Antibody Conjugates (ISACs) | Yes | |
| THIOMAB Drug Conjugate (TDC) | Yes | |
| T Cell Receptor Drug Conjugate (TCR DC) | Yes | Exploring |
| Antibody Glycan Conjugate (AGC) | Yes | |
| Protein-Protein Conjugate | Yes | |
| Peptide-Oligo Conjugate | Yes |
Biologics: Why Jubilant Biosys?
